stockportfolio.pro
CONMED Corporation (CNMD)
Healthcare · Medical Devices · NYSE
CONMED Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $763.52M | $796.39M | $859.63M | $955.10M | $862.46M | $1.01B | $1.05B | $1.24B | $1.31B | $1.37B |
| Gross profit | $408.33M | $431.04M | $469.11M | $524.72M | $460.30M | $568.04M | $571.25M | $676.25M | $733.03M | $750.48M |
| Net income | $14.66M | $55.49M | $40.85M | $28.62M | $9.52M | $62.54M | $-80.58M | $64.46M | $132.42M | $47.05M |
| Net margin | 1.9% | 7.0% | 4.8% | 3.0% | 1.1% | 6.2% | -7.7% | 5.2% | 10.1% | 3.4% |
Source: CONMED Corporation SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of CONMED Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CNMD in your portfolio →
About CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.
CONMED Corporation — frequently asked questions
What is CONMED Corporation's revenue?
CONMED Corporation (CNMD) reported revenue of $1.37B for fiscal year 2025, up 5.2% from the prior year, according to its SEC filings.
Is CONMED Corporation profitable?
Yes. CNMD earned net income of $47.05M in fiscal 2025, a net margin of 3.4%.
What is CNMD's P/E ratio?
CONMED Corporation trades at a price-to-earnings ratio of about 20.4 based on the latest data in our nightly-refreshed cache.
How fast is CONMED Corporation growing?
CNMD's revenue grew at roughly 9.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from CONMED Corporation's official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.